News

  • Diagnostics pioneers Abacus Diagnostica, Kaivogen and Labrox are now together Uniogen

    18.1.2022

    Three Finnish life science experts – Abacus Diagnostica, a frontrunner in molecular testing and rapid PCR test systems, Kaivogen, a specialist in immunoassays and antibody tests, and Labrox, an innovator of high technology laboratory instruments and diagnostic readers – announced in September 2021 that they are joining forces to form a global diagnostics pioneer. The share swap agreement between the companies has entered into force and the transaction has now been completed. The name of the new company is Uniogen Oy. The company is targeting the global market with a total solution under development for point-of-care testing for infectious diseases and cancers, among others.

    READ MORE


  • GenomEra® 2.0 assay kit for COVID-19 CE marked – introduces second-generation usability and sensitivity to PCR testing 

    10.2.2022

    Abacus Diagnostica, part of Uniogen, is launching its second-generation COVID-19 test, the GenomEra® SARS-CoV-2 2.0 Assay Kit in the European market. The assay kit has recently received European CE marking for In Vitro Diagnostic (IVD) medical devices.  

    It is intended for healthcare professionals, and it detects the SARS-CoV-2 virus in respiratory samples in 50 minutes. 

    • The assay kit provides rapid PCR test results with excellent sensitivity (98.3%) and high specificity (99.8%). 
       
    • The sample is collected to an inactivating sample collection media, which means that neither extensive safety measures nor dedicated PCR facilities are required. 
    • After a short and simple sample preparation, the assay process is fully automated. The results are automatically interpreted after 50 minutes. With one GenomEra® test system, up to four samples can be analysed at the same time. Capacity can be extended to 32 samples by combining up to eight instruments.  
    • The test performance is not affected by emergence of different COVID-19 variants, as the test simultaneously detects two different targets in the SARS-CoV-2 virus genome 
      – the RdRp and E genes. 

    Press release

    More information: SARS-CoV-2 2.0


  • Abacus Diagnostica, Kaivogen ja Labrox yhdistyvät

    14.9.2021

    Abacus Diagnostica, Kaivogen ja Labrox yhdistyvät ja muodostavat edelläkävijän globaaleille diagnostiikkamarkkinoille – Tavoitteena oikea diagnoosi sekä hoito ensimmäisellä potilaskäynnillä

    Turkulaiset biotekniikan huippuosaajat Abacus Diagnostica, Kaivogen ja Labrox ovat yhdistymässä kansainväliseksi diagnostiikkaratkaisujen edelläkävijäksi. Uusi yhtiö tulee tarjoamaan globaaleille markkinoille ainutlaatuisen vieritestauksen kokonaisratkaisun muun muassa infektio- ja syöpäsairauksien diagnostiikkaan. Se tuo yhteen maailman kärkeä olevan laite- ja kemiaosaamisen sekä tarjoaa terveydenhuollolle ja potilaille entistä nopeampaa, helpompaa ja kustannustehokkaampaa sairauksien tunnistamista. Yhdistyminen on tarkoitus saada päätökseen lokakuussa. Yhtiön nimi tullaan päättämään kuluvan syksyn aikana. 

    Taustalla olevilla kasvuyhtiöllä on vuosien kokemus diagnostiikan markkinoista: Abacus Diagnostica on molekyylitestauksen ja pika-PCR-testijärjestelmien suunnannäyttäjä, Kaivogen on immunomääritysten ja vasta-ainetestien erikoisosaaja ja Labrox on innovatiivinen laboratorioinstrumenttien kehittäjä. 

    Lehdistötiedote

    Abacus Diagnostica, Kaivogen and Labrox joining forces to form a global diagnostics pioneer – Enabling the right diagnosis and care at the patient’s first appointment

    Three Finnish biotech companies – Abacus Diagnostica, Kaivogen, and Labrox – are joining forces to form an international frontrunner in in vitro diagnostics. The new company will provide the global market with a unique total solution for point-of-care testing, including diagnostics for infectious diseases and cancers. It brings together some of the world’s leading instrumentation and biochemical knowhow, and it will offer healthcare providers and patients faster, easier and more cost-effective diagnostics. The transaction is to be completed in October. The name of the company will be decided during this autumn. 

    The three growth companies have years of experience in diagnostics: Abacus Diagnostica is a frontrunner in molecular testing and rapid PCR tests, Kaivogen specialises in immunoassays and antibody tests, and Labrox is an innovative developer of laboratory instruments. 

    Press release

  • New assay for rapid detection of SARS-CoV-2 variant strains now available for research use!

    22.3.2021

    Abacus Diagnostica has developed a SARS-CoV-2 Variants of Concern (VoC) Assay for the GenomEra® CDX platform. In addition to detecting all SARS-CoV-2 strains, the new test detects clinically significant deletions present in the variants first identified in the UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1). The test is now available as a Research Use Only -product.

  • GenomEra® multiplex assay is now CE marked and available!

    18.12.2020

    For inquiries, please contact info@abacusdiagnostica.com

  • Two open positions: Application / Service Engineer and Customer Support Scientist

    26.10.2020

    We are hiring. Apply by 8th of November 2020.

    Application Engineer / Service Engineer

    Customer Support Scientist

  • Influenza or COVID-19? Reliable diagnosis in 75 minutes with new multiplex assay

    23.9.2020

    Press release in Finnish

    Press release in English

  • GenomEra SARS-CoV-2 Assay Kit is now CE IVD approved and development for four-in-one test (FluA, FluB, RSV, SARS-CoV-2) is on-going

    17.7.2020

    GenomEra SARS-CoV-2 Assay Kit is now CE IVD approved and available. Please contact your local distributor or us for more information.

    In addition, we are developing a four-in-one test for detecting influenza A, influenza B, RSV and SARS-CoV-2. Targeted release is before winter Flu season 2020-2021.

  • Investment round is now open

    5.6.2020

    We warmly welcome all new investors!  
    #Crowdfunding #CapitalAtRisk

    https://abacusdiagnostica.com/invest

  • Special approval granted for SARS-CoV-2 test

    4.5.2020

    Finnish regulatory authority Fimea has granted special approval for Abacus to supply the GenomEra RUO SARS-CoV-2 test to Finnish markets.

    Press release in Finnish

  • First SARS-CoV-2 Test Kits Shipped

    30.3.2020

    Our team has been working hard on past weeks and today we shipped first GenomEra SARS-CoV-2 test kits for our customers.


    Press-release in Finnish: https://bit.ly/2UvaMC2

    edf


  • Abacus is now on Twitter

    26.3.2020

    Abacus is now on Twitter! We will tweet the latest news and more relaxed stories frequently. Some big news coming next week – stay tuned!  https://twitter.com/AbacusCDX #AbacusCDX

  • Recent publication: GenomEra C. difficile test demonstrates increased reliability for standalone molecular diagnostics

    11.3.2020

    While covid19 is spreading, there are still other worries to deal with. Standalone PCR testing for C. difficile diagnostics is often criticized for overdiagnosis of CDI. In a recent publication (doi:10.1128/JCM.01872-19) GenomEra routine samples were retested with two different toxin immunoassays and discrepant results were confirmed with culture or GeneXpert. Results shows perfect 100% PPV and excellent 99.7% NPV for GenomEra. Study reports insufficient sensitivities of 81.6% and 71.7% for two different toxin immunoassay from ArcDia and TechLab, respectively.

  • Announcement of a new distributor

    28.1.2020

    We are proud to announce our new distributor:

    -NexGen Molecular Supplies, South Africa.

    Please visit https://www.abacusdiagnostica.com/distributors/ to view the complete list. #pcr #abacusdiagnostica #molecular #diagnostics

  • New results from MRSA/SA AC and S.pneumoniae tests compared to culture.

    16.1.2020

    Poster P-124 from #Ricai 2019 poster session demostrates a study by Manon Prat et.al how our tests GenomEra MRSA/SA AC and GenomEra S.pneumoniae perform when suspected of superinfection with #influenza and #RSV. Using an optimized protocol and clinical samples, our tests correlate 100% with culture results. #moleclardiagnostics #pcr #poitiers #abacusdiagnostica #GenomEra

  • Season´s greetings

    20.12.2019

    We at Abacus Diagnostica would like to thank you and especially all our distributors and partners for this year and we all wish you a peaceful holiday season and a happy new year 2020! #pcr #moleculardiagnostics #seasonsgreetings #happynewyear

  • Abacus Diagnostica at Medica 2019!

    25.10.2019

    We will attend Medica next month in Düsseldorf. To book a meeting with us, please contact sales@abacusdiagnostica.com. We will be present the whole exhibition. See you there!

  • Evaluation results from FLU A/B + RSV assay

    26.9.2019

    If you somehow happened to miss the chance to review poster P111 from the latest ESCV event, please take a look at the attached pdf. There you can find some excellent evaluation results concerning our FLU A/B + RSV assay performed with GenomEra.

    https://www.abacusdiagnostica.com/wp-content/uploads/2019/09/Choquet_ESCV_2019.pdf

  • Great FLU A/B + RSV results at ESCV 2019!

    12.9.2019

    ESCV conference is taking place in Copenhagen. Dr. Pichon from CHU Poitiers, France is presenting first and excellent results from GenomEra Flu A/B + RSV evaluations, which they did in last winter. Go to check poster P111. Should you wish to select GenomEra system for next influenza season, please contact info@abacusdiagnostica.com to order a demo.

  • New publication of the upcoming direct GenomEra GBS assay for intrapartum screening is available

    16.5.2019

    Results shows equal sensitivity to culture and article highlights the usability of GenomEra.

    From the conclusions: “GenomEra GBS PCR assay has potential as an easy and rapid on-site test for intrapartum detection of vaginal carriage of GBS at a maternity ward to identify women in labor who should receive intrapartum antibiotic prophylaxis.”

    https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215314